论文部分内容阅读
近年来,药品不良反应损害事件频繁发生,但我国并没有明确具体的制度对受害人进行救济。而法制发达的国家和地区已建立较为完善具体的救济制度,因此通过分析考察国外及我国台湾地区相关救济模式,可为我国选择何种救济模式作出借鉴。研究目的:救济模式是药品不良反应损害救济制度的基础,只有确定了救济模式才能谈具体的制度构建,因此救济模式如何选择至关重要。研究方法:通过对诉讼救济模式、保险救济模式以及基金救济模式的比较分析,并结合我国的国情,选出较为适合我国的救济模式。研究成果:结合我国当前国情,应选择基金救济模式,再逐步过渡到基金-保险“二位一体”的救济模式,以期为受害者提供更全面的救济。
In recent years, adverse events of adverse drug reactions occur frequently, but our country does not have a clear and specific system to provide relief to the victims. The legal system in developed countries and regions have established more perfect specific relief system. Therefore, by analyzing the relevant relief models abroad and in Taiwan of our country, we can draw lessons from our country’s choice of relief model. Research purposes: Relief mode is the basis of harm relief system for adverse drug reactions. Only when the relief mode is established can we talk about the specific system construction. Therefore, it is of vital importance to choose the relief mode. Research Methods: By comparing litigation relief mode, insurance relief mode and fund relief mode, and combining with our country’s national conditions, we select the relief mode that is more suitable for our country. Research results: In light of China’s current national conditions, we should choose the fund relief model and then gradually transition to the fund-insurance “two in one ” relief model with a view to providing victims with more comprehensive relief.